loading
Turnstone Biologics Corp stock is traded at $0.3711, with a volume of 9,603. It is up +4.80% in the last 24 hours and down -4.85% over the past month. Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
See More
Previous Close:
$0.3541
Open:
$0.368
24h Volume:
9,603
Relative Volume:
0.05
Market Cap:
$8.58M
Revenue:
$81.89M
Net Income/Loss:
$-55.20M
P/E Ratio:
-0.1377
EPS:
-2.6959
Net Cash Flow:
$-67.40M
1W Performance:
+4.12%
1M Performance:
-4.85%
6M Performance:
-43.70%
1Y Performance:
-87.16%
1-Day Range:
Value
$0.361
$0.387
1-Week Range:
Value
$0.341
$0.407
52-Week Range:
Value
$0.341
$3.8782

Turnstone Biologics Corp Stock (TSBX) Company Profile

Name
Name
Turnstone Biologics Corp
Name
Phone
347-897-5988
Name
Address
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Name
Employee
81
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
TSBX's Discussions on Twitter

Compare TSBX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TSBX
Turnstone Biologics Corp
0.3711 8.58M 81.89M -55.20M -67.40M -2.6959
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-05-25 Downgrade Piper Sandler Overweight → Neutral
Nov-15-24 Downgrade BofA Securities Neutral → Underperform
Oct-14-24 Downgrade BofA Securities Buy → Neutral
Aug-16-23 Initiated SVB Securities Market Perform
Aug-15-23 Initiated BofA Securities Buy
Aug-15-23 Initiated Piper Sandler Overweight
View All

Turnstone Biologics Corp Stock (TSBX) Latest News

pulisher
Mar 13, 2025

Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

Turnstone Biologics stock plunges to 52-week low of $0.35 By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Turnstone Biologics stock plunges to 52-week low of $0.35 - Investing.com India

Mar 10, 2025
pulisher
Mar 09, 2025

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne

Mar 09, 2025
pulisher
Mar 04, 2025

Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Large Drop in Short Interest - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Turnstone Biologics Stock Hits 52-Week Low at $0.36 Amid Challenges - Investing.com India

Mar 03, 2025
pulisher
Mar 01, 2025

Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN

Mar 01, 2025
pulisher
Feb 12, 2025

Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 10, 2025

Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks

Feb 10, 2025
pulisher
Feb 08, 2025

Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World

Feb 08, 2025
pulisher
Feb 08, 2025

Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Feb 08, 2025
pulisher
Feb 07, 2025

Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter

Feb 07, 2025
pulisher
Feb 07, 2025

Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World

Feb 07, 2025
pulisher
Feb 06, 2025

A Look at Turnstone Biologics Corp (TSBX) Shares in the Recent Past Indicates Growth - SETE News

Feb 06, 2025
pulisher
Feb 05, 2025

TSBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 05, 2025
pulisher
Feb 05, 2025

Turnstone Biologics to explore strategic alternatives - The Pharma Letter

Feb 05, 2025
pulisher
Feb 05, 2025

Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75 - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Turnstone Biologics Corp (NASDAQ: TSBX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel

Feb 05, 2025
pulisher
Feb 05, 2025

Piper Sandler cuts Turnstone Biologics stock rating to neutral - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Turnstone Biologics halts TIDAL-01 development, seeks alternatives By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Ottawa-born Turnstone Biologics halting clinical studies, laying off staff - Ottawa Business Journal

Feb 05, 2025
pulisher
Feb 04, 2025

TSBX’s price-to-book ratio: An indicator of the company’s performance - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Turnstone Biologics Stops Tidal-01 Trials, Explores Strategic Alternatives; Shares Rise - Marketscreener.com

Feb 04, 2025
pulisher
Feb 04, 2025

Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes - TipRanks

Feb 04, 2025
pulisher
Feb 04, 2025

Turnstone Biologics Announces Plans to Explore Strategic Alternatives - The Manila Times

Feb 04, 2025
pulisher
Feb 04, 2025

Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review - Nasdaq

Feb 04, 2025
pulisher
Jan 29, 2025

Scailyte Announces Collaboration With Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors With TIL Therapy - ACCESS Newswire

Jan 29, 2025
pulisher
Jan 18, 2025

Head to Head Survey: Turnstone Biologics (NASDAQ:TSBX) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World

Jan 18, 2025
pulisher
Jan 12, 2025

Reviewing AlloVir (NASDAQ:ALVR) and Turnstone Biologics (NASDAQ:TSBX) - Defense World

Jan 12, 2025
pulisher
Jan 09, 2025

Turnstone Biologics (NASDAQ:TSBX) Stock Price Down 9.1% – Time to Sell? - Defense World

Jan 09, 2025
pulisher
Dec 18, 2024

Fmr LLC Boosts Stock Position in Turnstone Biologics Corp. (NASDAQ:TSBX) - Defense World

Dec 18, 2024
pulisher
Dec 05, 2024

Turnstone Biologics stock plunges to 52-week low of $0.44 By Investing.com - Investing.com Australia

Dec 05, 2024
pulisher
Dec 05, 2024

Turnstone Biologics stock plunges to 52-week low of $0.44 - Investing.com

Dec 05, 2024
pulisher
Nov 23, 2024

Turnstone Biologics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024
pulisher
Nov 15, 2024

Turnstone Biologics stock downgraded amid concerns over therapy scalability and funding - Investing.com

Nov 15, 2024
pulisher
Nov 13, 2024

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - The Manila Times

Nov 13, 2024
pulisher
Nov 12, 2024

Turnstone Biologics Faces Financial and Operational Challenges - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Turnstone Biologics Reports 25% Response Rate in Cancer Trial, Extends Cash Runway to 2026 | TSBX Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 06, 2024

Turnstone advances TIL therapy for solid tumors at SITC meeting By Investing.com - Investing.com Australia

Nov 06, 2024
pulisher
Nov 05, 2024

Turnstone advances TIL therapy for solid tumors at SITC meeting - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Turnstone Biologics Reveals Breakthrough TIL Cancer Treatment Data at SITC 2024 | TSBX Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 02, 2024

Warning: TSBX is at high risk of performing badly - MSN

Nov 02, 2024
pulisher
Oct 16, 2024

Turnstone Biologics (NASDAQ:TSBX) & Recursion Pharmaceuticals (NASDAQ:RXRX) Critical Contrast - Defense World

Oct 16, 2024
pulisher
Oct 14, 2024

BofA downgrades Turnstone stock, citing wait-and-see approach until 2025 data - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

Turnstone fires most staff in bid to to extend runway - The Pharma Letter

Oct 14, 2024

Turnstone Biologics Corp Stock (TSBX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):